CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
ARC-520 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02535416
NCT02535416Phase 1Completed

A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 at Varying Infusion Rates in Normal Adult Volunteers

Arrowhead Pharmaceuticals·interventional·Posted Aug 28, 2015·Updated Jan 13, 2026

In Brief

A Phase 1 clinical trial evaluating ARC-520, cetirizine, and 1 other intervention for Healthy. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Single doses of ARC-520 will be evaluated at varying infusion rates and by slow bolus push.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesAustralia
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 28, 2015
Enrollment StartSep 1, 2015
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.8 years ago

Interventions

ARC-520drug

cetirizinedrug

diphenhydraminedrug